Irish pharmaceutical company Elan has announced it’s to explore the possibility of splitting the company in two.

Any such move would see the €3 billion company separating its Athlone-based drug technology business from its bioneurology business.

The bioneurology side has had a key role in developing multiple sclerosis treatment Tysabri.